EMA of­fers free sci­en­tif­ic ad­vice for Covid-19 de­vel­op­ers

The EMA on Fri­day said it will ful­ly waive fees for sci­en­tif­ic ad­vice to drug­mak­ers de­vel­op­ing po­ten­tial treat­ments or vac­cines for the nov­el coro­n­avirus dis­ease (Covid-19).

The EMA typ­i­cal­ly charges fees rang­ing from €43,700-€87,600 ($48,430-$97,080) for sci­en­tif­ic ad­vice, though small- and medi­um-sized en­ti­ties and or­phan prod­uct de­vel­op­ers are el­i­gi­ble for re­duced fees.

The EMA says com­pa­nies should con­tact it “as soon as pos­si­ble with in­for­ma­tion about their pro­posed de­vel­op­ment” and pro­vides a ded­i­cat­ed email for in­quiries.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER